Natera, Inc. (NTRA)
- 2023-03-24 16:00:04
- Delayed Quote
Last56.65 +0.95 (+1.71%)
27.35 - 59.75
52 Week Range
Technical Indicators (Daily)
New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma
AUSTIN, Texas, March 22, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Cancer showing the prognostic and predictive utility of N...
Natera Announces Commercial Payor Coverage for Signatera™
AUSTIN, Texas, March 02, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the Company’s first commercial coverage policies for its molecular residual dise...
Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates
Natera (NTRA) delivered earnings and revenue surprises of 2.14% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...
Natera Reports Fourth Quarter and Full Year 2022 Financial Results
AUSTIN, Texas, February 28, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the fourth quarter and year ended December 31, 2022 and pr...
Is a Surprise Coming for Natera (NTRA) This Earnings Season?
Natera (NTRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season....
Disclaimer: The data contained in Super Surge website is not necessarily real-time nor accurate and may differ from the actual market data. Prices, volumes, ratios, charts and indicators are indicative and not appropriate for trading purposes. Super Surge doesn't bear any responsibility for any trading losses you might incur as a result of using this data.